Literature DB >> 336540

Cellular source of interferons in the circulation of mice with delayed hypersensitivity.

G Sonnenfeld, S B Salvin, J S Youngner.   

Abstract

The cellular origins of type I and type II interferons released into the circulation of mice with delayed hypersensitivity were investigated. We determined the effect of treatment with various immunosuppressive agents, including cyclophosphamide, cycloheximide, antithymocyte serum, and whole-body X-irradiation, on the release of interferons after intravenous injection of specific (old tuberculin) or nonspecific (lipopolysaccharide) stimuli. The results suggest that (i) a heterogeneous population of lymphocytes (T and B cells) produces type II interferon, (ii) type I interferon is produced by a different cell population, and (iii) type II interferon is produced de novo after challenge with old tuberculin of mice sensitized with Mycobacterium bovis BCG.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 336540      PMCID: PMC421228          DOI: 10.1128/iai.18.2.283-290.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

Review 1.  The biological activities of soluble lymphocyte products.

Authors:  E Pick; J L Turk
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

2.  Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity.

Authors:  J S Youngner; S B Salvin
Journal:  J Immunol       Date:  1973-12       Impact factor: 5.422

3.  Effect of antilymphocytic serum on circulating interferon in mice as a function of the inducer.

Authors:  J de Maeyer-Guignard; E de Maeyer
Journal:  Nat New Biol       Date:  1971-02-17

4.  Semi-micro, dye-binding assay for rabbit interferon.

Authors:  J A Armstrong
Journal:  Appl Microbiol       Date:  1971-04

5.  Cell interactions in the immune response in vitro. V. Specific collaboration via complexes of antigen and thymus-derived cell immunoglobulin.

Authors:  M Feldmann
Journal:  J Exp Med       Date:  1972-10-01       Impact factor: 14.307

6.  Specificity and nature of binding of antimacrophage serum.

Authors:  R Gallily; M Gornostansky
Journal:  Immunology       Date:  1972-03       Impact factor: 7.397

7.  Migration inhibitory factor and type II interferon in the circulation of mice sensitized with mycobacterial components.

Authors:  S B Salvin; E Ribi; D L Granger; J S Youngner
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

8.  T and B lymphocytes in the regulation of delayed hypersensitivity.

Authors:  R Neta; S B Salvin
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

9.  Control of interferon synthesis: effect of diethylaminoethyl-dextran on induction by polyinosinic-polycytidylic acid.

Authors:  J Vilcek; S L Barmak; E A Havell
Journal:  J Virol       Date:  1972-10       Impact factor: 5.103

10.  Evidence for a B-cell -like helper function in mixed lymphocyte culture between immunocompetent thymus cells.

Authors:  J W Kyminski; R T Smith
Journal:  J Exp Med       Date:  1975-02-01       Impact factor: 14.307

View more
  4 in total

1.  Viral abrogation of lymphocyte mitogenesis: induction of a soluble factor inhibitory to cellular proliferation.

Authors:  E Israel; B Beiss; M A Wainberg
Journal:  Immunology       Date:  1980-05       Impact factor: 7.397

2.  In vitro production and cellular origin of murine type II interferon.

Authors:  G Sonnenfeld; A D Mandel; T C Merigan
Journal:  Immunology       Date:  1979-04       Impact factor: 7.397

3.  Neurovirulence mutant of vesicular stomatitis virus with an altered target cell tropism in vivo.

Authors:  O T Preble; L E Costello; D D Huang; M A Barmada
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

4.  Type I and II interferons and migration inhibitory factor: production in Mycobacterium bovis BCG-infected mice desensitized with old tuberculin or lipopolysaccharide.

Authors:  J S Youngner; S B Salvin
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.